The SIK2 Inhibitor GRN-300 enhances PARP Inhibitor sensitivity and overcomes resistance by blocking homologous recombination (HR) DNA repair in ovarian cancer
NATIONAL CANCER INSTITUTE
· United States · $1.77M USD
We use cookies to keep your session secure, remember your preferences, and analyse site traffic with Google Analytics.
By continuing to use GrantFunds you agree to our
Privacy Policy
and
Terms of Use.